Vir Biotechnology, Inc. (NASDAQ:VIR), currently trading at $5.02, has seen its stock decline over 34% year-to-date, reflecting investor concerns despite its potential in treating serious infectious ...
Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company with a market capitalization of $644 million, has been making waves in the biotechnology sector with its focus on developing ...
Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage biopharmaceutical company, has been making waves in the biotech sector with its focus on developing treatments for serious infectious diseases ...
It's been a mediocre week for Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders, with the stock dropping 10% ...
Shares in Vir Biotechnology rose 74% on the strength of data from a blinded, eight-subject cohort in its phase 1 hepatitis B trial. The analysis suggests the neutralizing monoclonal antibody may be ...
Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.
Below is Validea's guru fundamental report for VIR BIOTECHNOLOGY INC (VIR). Of the 22 guru strategies we follow, VIR rates highest using our Value Investor model based on the published strategy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results